HDT Bio Corp.

Sep 19, 2025

FDA Greenlights HDT Bio's First-in-Class HDT-321 for the Prevention of Deadly Tick-Borne Disease

Jan 16, 2025

MalarVx licenses HDT Bio's repRNA/LION(TM) Technology for Novel Malaria Vaccine

Sep 17, 2024

HDT Bio to Help Spearhead RNA Vaccine Development in National Pandemic Preparedness Initiative

Aug 07, 2024

HDT Bio Publishes Peer-Reviewed Article Describing the Development of an RNA Vaccine to Prevent Infection and Disease Caused by Enterovirus D68

Jan 23, 2024

HDT Bio Receives $749,000 EZBAA Contract and Partners with BARDA Under Project NextGen's Enabler's Program